Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5695806 | 0.85 | PLA2G4B (0.67) | PLA2G4BMAOBMAOAMEN1KMT2A | |
| SCHEMBL16396254 | 0.79 | RAB9A (0.60) | MRGPRX4PLA2G4BMAOBMAOAMEN1 | |
| SCHEMBL23978213 | 0.78 | TP53 (0.47) | PLA2G4BMEN1KMT2AMAPTNPC1 | |
| SCHEMBL11265699 | 0.77 | MEN1 (0.70) | NR4A2PLA2G4BMAOBMAOAMEN1 | |
| SCHEMBL23978233 | 0.77 | POLB (0.62) | MRGPRX4NR4A2PLA2G4BMAOBMEN1 | |
| SCHEMBL2963612 | 0.77 | PLA2G4B (0.60) | MRGPRX4NR4A2PLA2G4BMAOBMAOA | |
| SCHEMBL27863133 | 0.77 | MAOB (0.67) | MRGPRX4MAOBMAOAMEN1KMT2A | |
| SCHEMBL8991408 | 0.76 | MAOB (0.79) | MRGPRX4NR4A2PLA2G4BMAOBMAOA | |
| SCHEMBL11658094 | 0.76 | CA12 (0.66) | NR4A2PLA2G4BMAOBMEN1KMT2A | |
| SCHEMBL22718882 | 0.76 | CA12 (0.66) | NR4A2PLA2G4BMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | MRGPRX4 4677/4885NR4A2 3359/4885PLA2G4B 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.